- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Insider Trading: Biocon, its designated person slapped Rs 14 lakh fine by SEBI
New Delhi: Markets regulator Sebi on Wednesday imposed a total fine of Rs 14 lakh on Biocon Ltd and its designated person for violation of market norms.
Designated person of the firm, Narendra Chirmule, who was employed with the company as senior vice president-R&D is facing a fine of Rs 5 lakh for trading in the company''s securities when the trading window was closed.
By doing so, he violated provisions of Prohibition of Insider Trading (PIT) norms.
Sebi noted that the trading window was closed by the compliance officer of Biocon from January 1-26, 2019 on account of declaration of quarterly financial results of the company for the quarter ended December 31, 2018, which were announced on January 24, 2019.
In accordance with market norms, the company has to notify the particulars of the trading details of the promoter/member of the promoter group /designated person /director, if the value of the securities traded is in excess of Rs 10 lakh, to the stock exchange within 2 trading days of receipt of the disclosure or from becoming aware of such information.
However, Biocon had informed the bourses after a delay of 262 days.
In addition, market norms require that violation of code of conduct (CoC) be informed to the regulator "promptly."
Biocon informed Sebi after 28 days of becoming aware of violation of company''s code of conduct.
In violation of norms, the company did not define the deadline for informing the violation of PIT Regulations.
"It is noted that the company had failed to prescribe any deadline within which it is required to inform Sebi of the violation of CoC," the regulator said.
The information which was made belatedly by the company cannot be construed to be a reasonable period, it added.
Consequently, Biocon is facing a total penalty of Rs 9 lakh for violating various provisions of PIT norms.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751